$1.11 Billion is the total value of GREAT POINT PARTNERS LLC's 34 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 72.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $127,618,000 | +24.8% | 3,876,600 | +4.1% | 11.48% | +40.5% |
ACAD | Buy | ACADIA PHARMACEUTICALS INC | $79,264,000 | -9.4% | 1,921,563 | +6.5% | 7.13% | +2.0% |
UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $64,718,000 | -13.7% | 640,773 | +3.4% | 5.82% | -2.9% |
CYTK | Buy | CYTOKINETICS INC | $55,197,000 | +54.0% | 2,549,525 | +67.7% | 4.96% | +73.3% |
GWPH | Buy | GW PHARMACEUTICALS PLCads | $50,645,000 | -8.3% | 520,232 | +15.6% | 4.56% | +3.2% |
MGNX | Buy | MACROGENICS INC | $38,042,000 | -9.2% | 1,510,215 | +0.7% | 3.42% | +2.2% |
AUPH | New | AURINIA PHARMACEUTICALS INC | $36,609,000 | – | 2,485,327 | +100.0% | 3.29% | – |
GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $36,154,000 | +5.6% | 655,676 | +20.9% | 3.25% | +18.9% |
SGMO | Buy | SANGAMO THERAPEUTICS INC | $15,023,000 | +6.1% | 1,589,724 | +0.6% | 1.35% | +19.3% |
CCXI | New | CHEMOCENTRYX INC | $13,877,000 | – | 253,230 | +100.0% | 1.25% | – |
TBIO | New | TRANSLATE BIO INC | $12,839,000 | – | 943,339 | +100.0% | 1.16% | – |
ALLO | New | ALLOGENE THERAPEUTICS INC | $12,400,000 | – | 328,817 | +100.0% | 1.12% | – |
XENT | New | INTERSECT ENT INC | $12,199,000 | – | 747,926 | +100.0% | 1.10% | – |
IVA | New | INVENTIVA SAads | $11,813,000 | – | 999,422 | +100.0% | 1.06% | – |
PBYI | Buy | PUMA BIOTECHNOLOGY INC | $11,120,000 | +1052.3% | 1,102,073 | +1091.4% | 1.00% | +1198.7% |
CALA | Buy | CALITHERA BIOSCIENCES INC | $10,069,000 | -15.7% | 2,918,581 | +29.0% | 0.91% | -5.1% |
KDMN | Buy | KADMON HLDGS INC | $9,800,000 | +183.3% | 2,500,000 | +270.0% | 0.88% | +219.6% |
LNTH | New | LANTHEUS HLDGS INC | $7,535,000 | – | 594,750 | +100.0% | 0.68% | – |
CYTK | New | CYTOKINETICS INCput | $5,477,000 | – | 253,000 | +100.0% | 0.49% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.